49
Views
26
CrossRef citations to date
0
Altmetric
Research Article

Is weight loss possible in patients treated with thiazolidinediones? Experience with a low-calorie diet

, , &
Pages 609-613 | Published online: 22 Sep 2008

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Keith G Tolman. (2011) The safety of thiazolidinediones. Expert Opinion on Drug Safety 10:3, pages 419-428.
Read now
Anthony Barnett, Josie Allsworth, Kevin Jameson & Rachel Mann. (2007) A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Current Medical Research and Opinion 23:7, pages 1493-1507.
Read now

Articles from other publishers (24)

Garima Bansal, Punniyakoti Veeraveedu Thanikachalam, Rahul K. Maurya, Pooja Chawla & Srinivasan Ramamurthy. (2020) An overview on medicinal perspective of thiazolidine-2,4-dione: A remarkable scaffold in the treatment of type 2 diabetes. Journal of Advanced Research 23, pages 163-205.
Crossref
Fahmida Alam, Md. Asiful Islam, Mafauzy Mohamed, Imran Ahmad, Mohammad Amjad Kamal, Richard Donnelly, Iskandar Idris & Siew Hua Gan. (2019) Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Scientific Reports 9:1.
Crossref
Judy Y. Shiau, Derek Y.F. So & Robert R. Dent. (2018) Effects on Diabetes Medications, Weight and Glycated Hemoglobin Among Adult Patients With Obesity and Type 2 Diabetes: 6-Month Observations From a Full Meal Replacement, Low-Calorie Diet Weight Management Program. Canadian Journal of Diabetes 42:1, pages 56-60.
Crossref
. (2015) Obesity and reproduction: a committee opinion. Fertility and Sterility 104:5, pages 1116-1126.
Crossref
Gandahari Rosa A. Carpio & Vivian A. Fonseca. (2014) Update on Safety Issues Related to Antihyperglycemic Therapy. Diabetes Spectrum 27:2, pages 92-100.
Crossref
Vivian Fonseca, Roberta McDuffie, Jorge Calles, Robert M. Cohen, Patricia Feeney, Mark Feinglos, Hertzel C. Gerstein, Faramarz Ismail-Beigi, Timothy M. Morgan, Rodica Pop-Busui & Matthew C. Riddle. (2013) Determinants of Weight Gain in the Action to Control Cardiovascular Risk in Diabetes Trial. Diabetes Care 36:8, pages 2162-2168.
Crossref
Curtis K. Argo, Julia C. Iezzoni, Abdullah M. S. Al-Osaimi & Stephen H. Caldwell. (2009) Thiazolidinediones for the Treatment in NASH. Journal of Clinical Gastroenterology 43:6, pages 565-568.
Crossref
Robert F. Kushner & Melissa Sujak. (2012) Prevention of Weight Gain in Adult Patients With Type 2 Diabetes Treated With Pioglitazone. Obesity 17:5, pages 1017-1022.
Crossref
David A. Sarruf, Fang Yu, Hong T. Nguyen, Diana L. Williams, Richard L. Printz, Kevin D. Niswender & Michael W. Schwartz. (2009) Expression of Peroxisome Proliferator-Activated Receptor-γ in Key Neuronal Subsets Regulating Glucose Metabolism and Energy Homeostasis. Endocrinology 150:2, pages 707-712.
Crossref
. (2008) Obesity and reproduction: an educational bulletin. Fertility and Sterility 90:5, pages S21-S29.
Crossref
A. Brunani, A. Caumo, S. Graci, G. Castagna, G. Viberti & A. Liuzzi. (2008) Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients. Diabetes, Obesity and Metabolism 10:6, pages 460-467.
Crossref
Annemiek M. C. P. Joosen, Arjen H. F. Bakker, Sander Kersten & Klaas R. Westerterp. (2008) The PPARγ ligand rosiglitazone influences triacylglycerol metabolism in non-obese males, without increasing the transcriptional activity of PPARγ in the subcutaneous adipose tissue. British Journal of Nutrition 99:3, pages 487-493.
Crossref
Glen Lutchman, Apurva Modi, David E. Kleiner, Kittichai Promrat, Theo Heller, Marc Ghany, Brian Borg, Rohit Loomba, T. Jake Liang, Ahalya Premkumar & Jay H. Hoofnagle. (2007) The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 46:2, pages 424-429.
Crossref
Janaka Karalliedde & Robin E Buckingham. (2007) Thiazolidinediones and their Fluid-Related Adverse Effects. Drug Safety 30:9, pages 741-753.
Crossref
Vivian A. Fonseca & Steven E. Kahn. (2006) Of Hopes and DREAMS: The Quest to Prevent Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism 91:12, pages 4762-4763.
Crossref
Amalia Gastaldelli, Yoshinori Miyazaki, Archana Mahankali, Rachele Berria, Maura Pettiti, Emma Buzzigoli, Eleuterio Ferrannini & Ralph A. DeFronzo. (2006) The Effect of Pioglitazone on the Liver. Diabetes Care 29:10, pages 2275-2281.
Crossref
Annemiek M. C. P. Joosen, Arjen H. F. Bakker, Maarten J. A. Gering & Klaas R. Westerterp. (2006) The effect of the PPARγ ligand rosiglitazone on energy balance regulation. Diabetes/Metabolism Research and Reviews 22:3, pages 204-210.
Crossref
Zachary. T Bloomgarden. (2006) Developments in Diabetes and Insulin Resistance. Diabetes Care 29:1, pages 161-167.
Crossref
D. S. H. Bell & F. Ovalle. (2006) Long-term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetes. Diabetes, Obesity and Metabolism 8:1, pages 110-115.
Crossref
Á. Rodríguez Bernardino, S. Cebrián Blanco & S. Durán García. (2005) Pioglitazona. Revisión de sus efectos metabólicos y sistémicos. Revista Clínica Española 205:12, pages 610-620.
Crossref
Suzanne M. Strowig & Philip Raskin. (2005) Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus. Diabetes, Obesity and Metabolism 7:6, pages 633-641.
Crossref
Suzanne M. Strowig & Philip Raskin. (2005) The Effect of Rosiglitazone on Overweight Subjects With Type 1 Diabetes. Diabetes Care 28:7, pages 1562-1567.
Crossref
Andrew J. DrexlerRichard W. NestoMartin J. AbrahamsonGeorge BakrisDavid BellJohn BrunzellParesh DandonaJaime DavidsonVivian FonsecaMichael FowlerRobert FryeThomas GilesSteven HaffnerNorman HollenbergWilla HsuehRonald LawJorge PlutzkyRobert RatnerJane ReuschAndrew SelwynJames SowersKathleen WyneLawrence H. Young. (2005) Evaluating the Cardiovascular Effects of the Thiazolidinediones and Their Place in the Management of Type 2 Diabetes in Relation to the Metabolic Syndrome. Metabolic Syndrome and Related Disorders 3:2, pages 147-173.
Crossref
Vivian Fonseca. (2003) Effect of thiazolidinediones on body weight in patients with diabetes mellitus. The American Journal of Medicine 115:8, pages 42-48.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.